Biotech Values

[DewDiligence]

MRX—I never thought this U.S. patent No. 5,908,838, which expires in 2018, and relates to the use of the Solodyn unique dissolution rate is very strong as it was rejected and then reexamined but I guess it is very hard to circumvent the claims and get a bioequivalent drug.

The patent did appear to be weak; however, the fact that Solodyn is a drug where getting the right effective dose matters greatly presumably helped MRX reach a more favorable settlement with the P-IV challengers than would otherwise have been the case for the kind of patent in dispute.